Novo Nordisk put a new Wegovy on US shelves this week. The 7.2 mg injectable form of the GLP-1 agonist is now commercially available — three times the drug’s standard 2.4 mg maintenance dose.
The original Wegovy topped out at 2.4 mg weekly. That was enough to make semaglutide a cultural moment and generate blockbuster revenue for Novo. But Eli Lilly’s Zepbound (tirzepatide) has been eating into that lead. Novo’s been under pressure to show it can compete on efficacy, not just brand recognition.
Patients who plateau at 2.4 mg now have somewhere to go without switching drugs. Prescribers eyeing Zepbound for stubborn cases have a reason to stay in the Wegovy ecosystem rather than exploring alternatives. It’s a retention move. Extend the ceiling before patients start looking elsewhere.
The GLP-1 obesity market is one of the most heavily contested in pharma right now. Both companies are fighting for every point of market share. Novo’s 7.2 mg launch isn’t just a new SKU. It’s a move to keep semaglutide competitive without waiting on new molecules or a platform change.
Lilly’s next move in obesity is already being closely watched. Novo won’t have this lane to itself for long.
Sarah Chen